Dexcom

Dexcom, Inc. has established itself as the global leader in continuous glucose monitoring (CGM) technology, revolutionizing diabetes management for millions of people worldwide. Founded in 1999 and headquartered in San Diego, California, Dexcom has transformed how individuals with diabetes monitor their glucose levels, moving beyond traditional fingerstick testing to provide real-time, continuous data that empowers better health outcomes. The company operates internationally with a research and development center in San Diego, manufacturing facilities in Mesa, Arizona, Batu Kawan, Malaysia, and Athenry, Ireland, serving approximately 2.8 to 2.9 million users globally as of 2024.

Dexcom's product portfolio centers on its flagship CGM systems, with the Dexcom G7 representing the latest generation of technology. The G7 is 60% smaller than its predecessor, features a 30-minute warmup period (compared to the G6's 2-hour warmup), and delivers best-in-class accuracy with a Mean Absolute Relative Difference (MARD) of 8.2%. In 2024, Dexcom expanded its market reach by launching Stelo, the first over-the-counter CGM system in the United States, designed for adults with Type 2 diabetes who do not use insulin. This strategic expansion into the OTC market positions Dexcom to serve a broader population interested in understanding how lifestyle factors impact glucose levels.

The company's financial performance reflects its market leadership and innovation. Dexcom generated $4.033 billion in revenue in fiscal 2024, representing an 11.34% increase over 2023, with Q4 2024 revenue reaching $1.114 billion. Net income for 2024 was $576.20 million, demonstrating profitable growth and strong unit economics. The company experienced 25% customer growth in 2024, expanding its user base significantly. Dexcom's market capitalization, while experiencing volatility throughout 2024, reflects its position as a major player in the diabetes technology market.

With approximately 9,600 employees, Dexcom has built a culture centered on its mission to "empower people to take control of health." The company's four core values—Think Big, Be Dependable, Listen, and Serve with Integrity—guide its approach to innovation, customer service, and employee engagement. Strategic partnerships, including a 2024 collaboration with ŌURA that integrates CGM data with the Oura Ring for comprehensive health insights, demonstrate Dexcom's commitment to expanding the ecosystem of connected health devices. As Dexcom prepares for a leadership transition with COO Jake Leach assuming the CEO role in January 2026, the company continues to push the boundaries of glucose monitoring technology and expand access to life-changing CGM systems.